Protocol Ledger

NCT04784559 · Phase III · TERMINATED

Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection

Interventional Phase III clinical trial protocol NCT04784559 sponsored by PharmaMar in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-06-04 Enrollment: 205 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04784559
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)205 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04784559
Protocol FieldVerified Registry Value
NCT IdentifierNCT04784559
Consolidated Lead SponsorPharmaMar
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment205 participants (ACTUAL)
Registered Start Date2021-06-04
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04784559
Hospital Research SiteLocationSite Profile
Hospital Universitari Germans Trias i PujolBadalona, SpainOpen Hospital Dossier ->
Hospital General Universitario de AlicanteAlicante, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI